{"id":11932,"date":"2026-10-20T20:03:34","date_gmt":"2026-10-21T00:03:34","guid":{"rendered":"https:\/\/crassulapharma.com\/?page_id=11932"},"modified":"2026-10-22T13:47:39","modified_gmt":"2026-10-22T17:47:39","slug":"glycedil-duo","status":"publish","type":"page","link":"https:\/\/crassulapharma.com\/es\/glycedil-duo\/","title":{"rendered":"Glycedil Duo"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"11932\" class=\"elementor elementor-11932\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-eb6792d e-con-full e-flex e-con e-parent\" data-id=\"eb6792d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-baa83ff elementor-widget elementor-widget-html\" data-id=\"baa83ff\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<!doctype html>\n<html lang=\"en\">\n<head>\n<meta charset=\"utf-8\">\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1\">\n<title>Glycedil Duo\u00ae (Sitagliptin \/ Metformin) \u2013 Crassula<\/title>\n<meta name=\"description\" content=\"Glycedil Duo combines Sitagliptin and Metformin in an oral-release tablet, specifically designed for the management of type 2 diabetes in adults. This combination takes advantage of the complementary mechanisms of both drugs to improve glycemic control, with a low risk of hypoglycemia when used without insulin or sulfonylureas.\">\n<link rel=\"preload\" href=\"fonts\/poppins-latin-600-normal.woff2\" as=\"font\" type=\"font\/woff2\" crossorigin>\n<link rel=\"preload\" href=\"fonts\/ibm-plex-sans-latin-400-normal.woff2\" as=\"font\" type=\"font\/woff2\" crossorigin>\n<style>\n@font-face{font-family:\"Poppins\";font-weight:500;font-style:normal;font-display:swap;src:url(fonts\/poppins-latin-500-normal.woff2) format(\"woff2\")}\n@font-face{font-family:\"Poppins\";font-weight:600;font-style:normal;font-display:swap;src:url(fonts\/poppins-latin-600-normal.woff2) format(\"woff2\")}\n@font-face{font-family:\"IBM Plex Sans\";font-weight:400;font-style:normal;font-display:swap;src:url(fonts\/ibm-plex-sans-latin-400-normal.woff2) format(\"woff2\")}\n@font-face{font-family:\"IBM Plex Sans\";font-weight:500;font-style:normal;font-display:swap;src:url(fonts\/ibm-plex-sans-latin-500-normal.woff2) format(\"woff2\")}\n\n:root{\n  --teal-deep:#3c0c2c; --teal-head:#5e1447; --teal:#7c215d; --teal-2:#8b2a6b; --teal-3:#5a1543;\n  --red:#9a2279; --accent-text:#5a1543; --green:#6aae57;\n  --action-teal:#7c215d; --ink:#2e2631; --ink-muted:#5a4b57; --surface:#faf3f7; --note:#faeff5;\n  --line:#eedfe8;\n  --ease-out:cubic-bezier(.23,1,.32,1);\n  --font-head:\"Poppins\",system-ui,sans-serif;\n  --font-body:\"IBM Plex Sans\",system-ui,sans-serif;\n  --cx-gutter:clamp(20px,5vw,48px);\n  --cx-max:1120px;\n}\n*{box-sizing:border-box;margin:0}\nhtml{scroll-behavior:smooth;scroll-padding-top:24px;-webkit-text-size-adjust:100%}\nbody{font-family:var(--font-body);font-size:17px;line-height:1.6;color:var(--ink);background:#fff;-webkit-font-smoothing:antialiased;text-rendering:optimizeLegibility}\nimg{max-width:100%;height:auto;display:block}\na{color:var(--action-teal)}\n:focus-visible{outline:2px solid var(--action-teal);outline-offset:2px;border-radius:6px}\n.skip{position:absolute;left:12px;top:-60px;background:var(--ink);color:#fff;padding:10px 16px;border-radius:999px;z-index:100;text-decoration:none;font-family:var(--font-head);font-weight:500}\n.skip:focus{top:12px}\n.cx-wrap{width:100%;max-width:var(--cx-max);margin-inline:auto;padding-inline:var(--cx-gutter)}\n\n\/* Buttons *\/\n.btn{white-space:nowrap;display:inline-flex;align-items:center;justify-content:center;gap:8px;min-height:48px;padding:16px 28px;border-radius:6px;font:500 16px\/1 var(--font-head);text-decoration:none;cursor:pointer;border:1.5px solid transparent;\n  transition:background-color 150ms var(--ease-out),transform 150ms var(--ease-out),box-shadow 150ms var(--ease-out),color 150ms var(--ease-out)}\n.btn:active{transform:scale(.97)}\n.btn-primary{background:#fff;color:var(--teal-deep)}\n.btn-secondary{background:transparent;border-color:rgba(255,255,255,.85);color:#fff}\n.btn-sm{padding:12px 22px;min-height:48px;font-size:15px}\n@media (hover:hover) and (pointer:fine){\n  .btn-primary:hover{background:#f3dfea;transform:translateY(-2px)}\n  .btn-secondary:hover{background:#fff;color:var(--teal-deep);transform:translateY(-2px)}\n}\n\n\/* Hero *\/\n.hero{position:relative;background:linear-gradient(125deg,#3c0c2c 0%,#5a1543 50%,#8f2a6c 100%);overflow:hidden;isolation:isolate;color:#fff}\n.hero::before{content:\"\";position:absolute;inset:0;z-index:-1;background:repeating-linear-gradient(115deg,rgba(255,255,255,.045) 0 1px,transparent 1px 46px)}\n.hero canvas{position:absolute;inset:0;width:100%;height:100%;z-index:-1;pointer-events:none}\n.hero::after{content:\"\";position:absolute;left:-6%;right:-6%;bottom:-1px;height:clamp(36px,6vw,70px);background:#fff;border-radius:50% 50% 0 0\/100% 100% 0 0}\n.hero .cx-wrap{display:grid;grid-template-columns:1fr 1fr;align-items:center;gap:clamp(24px,4vw,48px);padding-block:clamp(50px,8vw,50px) clamp(96px,11vw,132px)}\n.tag{display:inline-block;font:500 12px\/1 var(--font-body);letter-spacing:.12em;text-transform:uppercase;color:#fff;border:1px solid rgba(255,255,255,.4);border-radius:6px;padding:11px 16px;background:rgba(255,255,255,.08);margin-bottom:28px}\nh1{font:600 clamp(40px,7vw,64px)\/1.08 var(--font-head);letter-spacing:-.02em;color:#fff}\nh1 sup{font-size:.34em;vertical-align:top;position:relative;top:.55em;margin-left:.08em;letter-spacing:0}\n.generic{font:500 clamp(22px,3vw,28px)\/1.3 var(--font-head);color:rgba(255,255,255,.88);margin-top:10px}\n.strengths{display:flex;gap:10px;margin-top:26px;flex-wrap:wrap}\n.chip{font:600 20px\/1 var(--font-head);padding:12px 20px;border-radius:12px;color:#fff;font-variant-numeric:tabular-nums}\n.chip.t{background:#fff;color:var(--teal-head)}.chip.g{background:var(--red)}\n.cta-row{display:flex;gap:12px;flex-wrap:wrap;margin-top:36px}\n.hero-art{position:relative;aspect-ratio:1.08\/1;width:110%;margin-right:-10%}\n.hero-art img{position:absolute}\n.hero-art .a{left:0;top:18%;width:56%}\n.hero-art .b{right:0;top:38%;width:62%}\n@media (max-width:860px){.hero .cx-wrap{grid-template-columns:1fr}.hero-art{max-width:600px;width:100%;margin:0 auto}}\n\n\/* Spec strip *\/\n.specs{margin-top:-70px;position:relative;z-index:2}\n.specs ul{list-style:none;padding:0;display:grid;grid-template-columns:repeat(4,1fr);background:#fff;border:1px solid var(--line);border-radius:20px;box-shadow:0 14px 34px -18px rgba(60,12,44,.30)}\n.specs ul{overflow:hidden}\n.specs li{position:relative;transition:background-color 250ms var(--ease-out),transform 250ms var(--ease-out);display:flex;align-items:center;gap:14px;padding:22px 24px;border-left:1px solid var(--line)}\n.specs li:first-child{border-left:0}\n.specs li::after{content:\"\";position:absolute;left:0;right:0;bottom:0;height:3px;background:linear-gradient(90deg,var(--teal-2),var(--green));transform:scaleX(0);transform-origin:left;transition:transform 350ms var(--ease-out)}\n.specs .ico{transition:transform 300ms var(--ease-out),background-color 250ms var(--ease-out),box-shadow 300ms var(--ease-out)}\n.specs dd{transition:transform 300ms var(--ease-out),color 250ms var(--ease-out)}\n@media (hover:hover){\n  .specs li:hover{background:var(--note)}\n  .specs li:hover::after{transform:scaleX(1)}\n  .specs li:hover .ico{transform:translateY(-3px) scale(1.12) rotate(-6deg);background:var(--teal-deep);box-shadow:0 10px 18px -8px rgba(60,12,44,.55)}\n  .specs li:hover dd{color:var(--teal);transform:translateX(3px)}\n}\n.ico{flex:none;width:42px;height:42px;border-radius:50%;background:var(--action-teal);display:grid;place-items:center;color:#fff}\n.ico svg{width:20px;height:20px;stroke:currentColor;fill:none;stroke-width:1.8;stroke-linecap:round;stroke-linejoin:round}\n.specs dt{font:500 11px\/1.2 var(--font-body);letter-spacing:.12em;text-transform:uppercase;color:var(--ink-muted)}\n.specs dd{font:600 15.5px\/1.3 var(--font-head);margin-top:4px;color:var(--ink)}\n@media (max-width:900px){.specs ul{grid-template-columns:1fr 1fr}.specs li:nth-child(3){border-left:0}.specs li:nth-child(n+3){border-top:1px solid var(--line)}}\n@media (max-width:480px){.specs ul{grid-template-columns:1fr}.specs li{border-left:0!important}.specs li+li{border-top:1px solid var(--line)}}\n\n\/* Sections *\/\nsection{padding-block:clamp(56px,8vw,96px)}\n.h2{color:var(--teal-head);display:flex;align-items:center;gap:14px;font:600 clamp(28px,4vw,36px)\/1.15 var(--font-head);letter-spacing:-.01em;margin-bottom:28px}\n.h2::before{content:\"\";flex:none;width:6px;align-self:stretch;min-height:1.1em;border-radius:4px;background:linear-gradient(var(--teal-2),var(--green))}\n.prose p{max-width:68ch;color:var(--ink)}\n.prose p+p{margin-top:14px}\n.prose strong{font-weight:500;color:var(--action-teal);font-family:var(--font-head)}\n.about{padding-top:clamp(64px,9vw,104px)}\n\n\/* Indications *\/\n.indications{background:#fff;padding-top:0}\n.cards{display:grid;grid-template-columns:repeat(2,1fr);gap:20px}\n.card{background:var(--surface);border:1px solid var(--line);border-radius:20px;padding:28px;transition:transform 250ms var(--ease-out),box-shadow 250ms var(--ease-out),border-color 250ms var(--ease-out)}\n.card{position:relative;overflow:hidden}\n.card::after{content:\"\";position:absolute;left:0;right:0;bottom:0;height:4px;background:linear-gradient(90deg,var(--teal-2),var(--green));transform:scaleX(0);transform-origin:left;transition:transform 400ms var(--ease-out)}\n.card .ico{transition:transform 300ms var(--ease-out),background-color 250ms var(--ease-out),color 250ms var(--ease-out)}\n@media (hover:hover){\n  .card:hover{transform:translateY(-8px);box-shadow:0 24px 40px -22px rgba(60,12,44,.45);border-color:#d9b9cc;background:#fff}\n  .card:hover::after{transform:scaleX(1)}\n  .card:hover .ico{background:var(--teal);color:#fff;transform:rotate(-8deg) scale(1.12)}\n}\n.card .ico{width:38px;height:38px;background:#fff;color:var(--action-teal);border:1px solid var(--line);border-radius:12px;margin-bottom:18px}\n.card h3{color:var(--teal-head);font:600 19px\/1.3 var(--font-head);color:var(--ink);margin-bottom:10px}\n.card p{color:var(--ink-muted);font-size:16.5px}\n.card em{font-style:italic}\n@media (max-width:760px){.cards{grid-template-columns:1fr}}\n\n\/* Presentations *\/\n.presentations{background:var(--surface)}\n.pres{display:grid;grid-template-columns:1fr 1fr;gap:20px}\n.pcard{display:flex;align-items:center;gap:24px;background:#fff;border:1px solid var(--line);border-radius:20px;padding:26px 28px;position:relative;overflow:hidden;transition:transform 250ms var(--ease-out),box-shadow 250ms var(--ease-out)}\n.pcard::before{content:\"\";position:absolute;left:0;top:0;bottom:0;width:6px;background:var(--c)}\n.pcard::before{transition:width 300ms var(--ease-out)}\n.dose{transition:transform 350ms var(--ease-out)}\n@media (hover:hover){\n  .pcard:hover{transform:translateY(-6px);box-shadow:0 24px 40px -22px rgba(60,12,44,.45)}\n  .pcard:hover::before{width:14px}\n  .pcard:hover .dose{transform:scale(1.08) translateX(4px)}\n}\n.dose{font:600 clamp(40px,6vw,52px)\/1 var(--font-head);color:var(--c);letter-spacing:-.02em;white-space:nowrap}\n.dose small{font:500 18px\/1 var(--font-head);letter-spacing:0;margin-left:4px}\n.pcard h3{color:var(--teal-head);font:600 17px\/1.35 var(--font-head);margin-bottom:6px}\n.pcard p{color:var(--ink-muted);font-size:16px;line-height:1.5}\n@media (max-width:760px){.pres{grid-template-columns:1fr}}\n\n\/* Mechanism *\/\n.mech-intro{max-width:78ch;margin-bottom:44px}\n.mech-intro strong{font-weight:500;color:var(--action-teal);font-family:var(--font-head)}\n.mech-grid{display:grid;grid-template-columns:1.1fr .9fr;gap:clamp(28px,5vw,64px);align-items:start}\n.steps{list-style:none;padding:0;position:relative}\n.steps::before{content:\"\";position:absolute;left:19px;top:20px;bottom:30px;width:2px;background:linear-gradient(var(--action-teal),rgba(124,33,93,.08));transform-origin:top;transform:scaleY(var(--line,0));transition:transform 900ms var(--ease-out)}\n.steps li{position:relative;padding-left:64px;padding-bottom:34px;transition:transform 300ms var(--ease-out)}\n.num{transition:transform 300ms var(--ease-out),background-color 250ms var(--ease-out)}\n.steps h3{transition:color 250ms var(--ease-out)}\n@media (hover:hover){.steps li:hover{transform:translateX(6px)}.steps li:hover .num{transform:scale(1.18);background:var(--teal-deep)}.steps li:hover h3{color:var(--teal)}}\n.steps li:last-child{padding-bottom:0}\n.num{position:absolute;left:0;top:0;width:40px;height:40px;border-radius:50%;background:var(--action-teal);color:#fff;display:grid;place-items:center;font:600 16px\/1 var(--font-head);box-shadow:0 0 0 5px #fff}\n.steps h3{color:var(--teal-head);font:600 19px\/1.3 var(--font-head);color:var(--ink);margin:6px 0 6px}\n.steps p{color:var(--ink-muted)}\n@media (max-width:900px){.mech-grid{grid-template-columns:1fr}}\n\n\/* Flow diagram *\/\n.flow{background:var(--surface);border:1px solid var(--line);border-radius:24px;padding:28px clamp(18px,3vw,32px) 32px;text-align:center}\n.flow-title{font:600 12px\/1 var(--font-body);letter-spacing:.14em;text-transform:uppercase;color:var(--ink-muted);margin-bottom:22px}\n.node{display:block;margin-inline:auto;background:#fff;border:1.5px solid #e3cdd9;border-radius:12px;padding:10px 16px;max-width:300px;font:600 14px\/1.3 var(--font-head);color:var(--ink);opacity:0;transition:border-color 250ms var(--ease-out),box-shadow 250ms var(--ease-out),transform 250ms var(--ease-out)}\n.node small{display:block;font:400 12px\/1.3 var(--font-body);color:var(--ink-muted);margin-top:2px}\n.node.primary{background:var(--action-teal);border-color:var(--action-teal);color:#fff;border-radius:999px;padding:14px 20px;font-size:16px}\n.node.primary small{color:#fff;font-size:12.5px}\n.node.end{background:var(--action-teal);border-color:var(--action-teal);color:#fff;padding:14px 18px;font-size:15px}\n.flow.in .node{opacity:1;animation:rise 450ms var(--ease-out) backwards;animation-delay:calc(var(--i)*220ms)}\n@media (hover:hover){.flow.in .node:hover{transform:translateY(-3px) scale(1.03);border-color:var(--teal);box-shadow:0 10px 20px -12px rgba(60,12,44,.45)}}\n.link-v{display:flex;flex-direction:column;align-items:center;height:30px;position:relative;opacity:0;transition:opacity 400ms var(--ease-out);transition-delay:calc(var(--i)*220ms)}\n.flow.in .link-v{opacity:1}\n.link-v::before{content:\"\";flex:1;width:2px;background:var(--action-teal)}\n.link-v::after{content:\"\";width:0;height:0;border:6px solid transparent;border-top:8px solid var(--action-teal);border-bottom:0}\n.link-v.stop::after{border:0;width:22px;height:2px;background:var(--red)}\n.link-v.stop::before{background:var(--red)}\n.link-v.stop span{position:absolute;left:calc(50% + 14px);top:50%;transform:translateY(-50%);font:400 11.5px\/1 var(--font-body);color:var(--accent-text)}\n.pair{display:grid;grid-template-columns:1fr 1fr;gap:10px;max-width:340px;margin-inline:auto}\n.pair .node{max-width:none;font-size:13px;padding:10px 10px}\n.fork{max-width:340px;height:28px;margin-inline:auto;position:relative;opacity:0;transition:opacity 400ms var(--ease-out);transition-delay:calc(var(--i)*220ms)}\n.flow.in .fork{opacity:1}\n.fork::before{content:\"\";position:absolute;left:25%;right:25%;top:0;height:14px;border:2px solid var(--action-teal);border-bottom:0;border-radius:0}\n.fork::after{content:\"\";position:absolute;left:50%;top:-14px;height:14px;width:2px;background:var(--action-teal)}\n.fork i{position:absolute;top:14px;width:0;height:0;border:6px solid transparent;border-top:8px solid var(--action-teal);border-bottom:0}\n.fork i:first-child{left:calc(25% - 6px)}.fork i:last-child{right:calc(25% - 6px)}\n.pair-wrap{display:grid;gap:10px}\n.down-merge{margin-top:2px}\n\n\n\/* Product additions *\/\n.pcard.wide{display:grid;grid-template-columns:auto 1fr;gap:clamp(20px,4vw,48px)}\n.pgrid{display:grid;grid-template-columns:repeat(3,1fr);gap:20px}\n.pgrid dt{font:500 11px\/1.2 var(--font-body);letter-spacing:.12em;text-transform:uppercase;color:var(--ink-muted)}\n.pgrid dd{font:600 16px\/1.35 var(--font-head);color:var(--teal-head);margin-top:6px}\n@media (max-width:760px){.pcard.wide{grid-template-columns:1fr;gap:16px}.pgrid{grid-template-columns:1fr}}\n.dn{color:var(--red);font-weight:600}\n.node.end.clock{display:flex;align-items:center;justify-content:center;gap:12px;max-width:260px;margin-top:14px;text-align:left;padding:12px 18px}\n.node.end.clock svg{flex:none;width:34px;height:34px;padding:7px;border-radius:50%;background:var(--red);stroke:#fff;fill:none;stroke-width:2;stroke-linecap:round;stroke-linejoin:round}\n.node.end.clock b{display:block;font:600 15px\/1.2 var(--font-head)}\n.node.end.clock small{color:#fff;opacity:.92;font-size:12px;margin-top:2px}\n.pair{margin-top:0}\n.steps p sup{font-size:.7em;line-height:0}\n\n\n\/* Media + FAQ additions *\/\n.split{display:grid;grid-template-columns:1.1fr .9fr;gap:clamp(28px,5vw,72px);align-items:center}\n.split.rev{grid-template-columns:.9fr 1.1fr}\n.media-wrap{position:relative;isolation:isolate}\n.media-wrap::before{content:\"\";position:absolute;right:-14px;bottom:-14px;width:62%;height:62%;border-radius:26px;background:linear-gradient(135deg,var(--teal-2),var(--green));opacity:.2;z-index:-1;transition:transform 500ms var(--ease-out),opacity 500ms var(--ease-out)}\n.split.rev .media-wrap::before{right:auto;left:-14px}\n.media{position:relative;border-radius:24px;overflow:hidden;aspect-ratio:4\/4;background:var(--surface)}\n.media img{width:100%;height:100%;object-fit:cover;display:block;transition:transform 900ms var(--ease-out)}\n@media (hover:hover){.media-wrap:hover .media img{transform:scale(1.05)}.media-wrap:hover::before{transform:translate(6px,6px);opacity:.32}.split.rev .media-wrap:hover::before{transform:translate(-6px,6px)}}\n@media (max-width:860px){.split,.split.rev{grid-template-columns:1fr}.split.rev .media-wrap{order:2}.media-wrap{max-width:560px}}\n.faq{background:var(--surface)}\n.faq-list{display:grid;gap:12px;max-width:880px}\n.faq-item{background:#fff;border:1px solid var(--line);border-radius:16px;overflow:hidden;transition:border-color 250ms var(--ease-out),box-shadow 250ms var(--ease-out),transform 250ms var(--ease-out)}\n@media (hover:hover){.faq-item:hover{transform:translateY(-2px);border-color:#d9b9cc;border-color:color-mix(in srgb,var(--teal-2) 40%,var(--line));box-shadow:0 16px 30px -22px rgba(60,12,44,.4)}}\n.faq-item.open{border-color:var(--teal-2);box-shadow:0 18px 34px -24px rgba(60,12,44,.45)}\n.faq-q{width:100%;display:flex;align-items:center;justify-content:space-between;gap:16px;min-height:48px;padding:20px 24px;background:none;border:0;cursor:pointer;text-align:left;font:600 17px\/1.4 var(--font-head);color:var(--teal-head)}\n.faq-q:focus-visible{outline-offset:-4px}\n.faq-ico{flex:none;width:34px;height:34px;border-radius:10px;background:var(--surface);display:grid;place-items:center;transition:background-color 250ms var(--ease-out),transform 350ms var(--ease-out)}\n.faq-ico svg{width:16px;height:16px;stroke:var(--teal);stroke-width:2.2;stroke-linecap:round;fill:none;transition:stroke 250ms var(--ease-out)}\n.faq-item.open .faq-ico{background:var(--teal);transform:rotate(45deg)}\n.faq-item.open .faq-ico svg{stroke:#fff}\n.faq-a{display:grid;grid-template-rows:0fr;transition:grid-template-rows 350ms var(--ease-out)}\n.faq-item.open .faq-a{grid-template-rows:1fr}\n.faq-a>div{overflow:hidden;visibility:hidden;transition:visibility 0s linear 350ms}\n.faq-item.open .faq-a>div{visibility:visible;transition-delay:0s}\n.faq-a p{padding:0 24px 22px;max-width:70ch;color:var(--ink-muted)}\n.faq-a p+p{padding-top:0;margin-top:-8px}\n\n\n\/* Note with background image *\/\n.note-box.has-bg{position:relative;overflow:hidden;isolation:isolate;border:0;color:#fff;min-height:260px;display:flex;flex-direction:column;justify-content:center;padding:clamp(32px,5vw,64px)}\n.note-box.has-bg .bg{position:absolute;inset:0;z-index:-2;overflow:hidden}\n.note-box.has-bg .bg img{width:100%;height:100%;object-fit:cover;object-position:0% 100%;display:block;transform:scale(1.02);transition:transform 1000ms var(--ease-out)}\n.note-box.has-bg::after{content:\"\";position:absolute;inset:0;z-index:-1;background:linear-gradient(100deg,rgba(var(--ov),.93) 0%,rgba(var(--ov),.86) 60%,rgba(var(--ov),.78) 100%)}\n.note-box.has-bg h3{color:#fff}\n.note-box.has-bg h3 .ico{background:rgba(255,255,255,.16);box-shadow:inset 0 0 0 1px rgba(255,255,255,.28)}\n.note-box.has-bg p{color:#fff;max-width:72ch;font-size:17.5px}\n.note-box.has-bg p::before{background:var(--green)}\n@media (hover:hover){.note-box.has-bg:hover .bg img{transform:scale(1.08)}}\n\/* Rounded-corner fix: clip every layer to the radius so hover scale never squares the corners *\/\n.note-box.has-bg{border-radius:20px;clip-path:inset(0 round 20px)}\n@media (hover:hover){.note-box.has-bg:hover{transform:translate3d(0,-4px,0);box-shadow:none}}\n.note-box.has-bg .bg,.note-box.has-bg .bg img,.note-box.has-bg::after{border-radius:20px}\n.note-box.has-bg .bg img{will-change:transform}\n\n\n\/* Note *\/\n.note{padding-block:0 clamp(40px,6vw,64px)}\n.note-box{background:var(--note);border:1px solid #eedfe8;border-radius:20px;padding:26px clamp(20px,3vw,32px)}\n.note-box{transition:transform 300ms var(--ease-out),box-shadow 300ms var(--ease-out)}\n@media (hover:hover){.note-box:hover{transform:translateY(-4px);box-shadow:0 22px 38px -26px rgba(60,12,44,.5)}}\n.note-box h3{color:var(--teal-head);display:flex;align-items:center;gap:12px;font:600 19px\/1.2 var(--font-head);margin-bottom:12px}\n.note-box h3 .ico{width:38px;height:38px;border-radius:12px;background:var(--action-teal)}\n.note-box p{position:relative;padding-left:20px;color:var(--ink)}\n.note-box p::before{content:\"\";position:absolute;left:0;top:.7em;width:8px;height:8px;border-radius:50%;background:var(--teal-2)}\n\n\/* Quality *\/\n.quality{padding-top:96px}\n.qbox{border:1px solid var(--line);border-radius:20px;padding:clamp(22px,3vw,34px);box-shadow:0 14px 34px -24px rgba(14,42,51,.25)}\n.qbox h2{font:600 22px\/1.2 var(--font-head);margin-bottom:24px}\n.qgrid{display:grid;grid-template-columns:auto 1fr 1fr;gap:clamp(20px,3vw,40px);align-items:center}\n.gmp{width:112px;height:112px;object-fit:contain;flex:none;filter:drop-shadow(0 6px 12px rgba(60,12,44,.18));transition:transform 500ms var(--ease-out),filter 500ms var(--ease-out)}\n@media (hover:hover){.gmp:hover{transform:scale(1.08);filter:drop-shadow(0 10px 18px rgba(60,12,44,.24))}}\n.check{display:flex;gap:14px;color:var(--ink-muted);font-size:16px;line-height:1.55}\n.check{transition:transform 300ms var(--ease-out)}\n@media (hover:hover){.check:hover{transform:translateY(-4px)}.check:hover svg{transform:scale(1.18) rotate(-6deg)}}\n.check svg{transition:transform 300ms var(--ease-out);flex:none;width:26px;height:26px;stroke:var(--green);fill:none;stroke-width:1.8;stroke-linecap:round;stroke-linejoin:round;margin-top:2px}\n@media (max-width:900px){.qgrid{grid-template-columns:1fr;align-items:start}}\n\n\/* Reveal *\/\n.rv{opacity:0}\n.rv.in{opacity:1;animation:rise 600ms var(--ease-out) backwards;animation-delay:calc(var(--d,0)*80ms)}\n@keyframes rise{from{opacity:0;transform:translateY(18px)}to{opacity:1;transform:none}}\n.hero-art img{opacity:0;transition:opacity 700ms var(--ease-out),transform 900ms var(--ease-out)}\n.loaded .hero-art img{opacity:1;transform:none}\n@keyframes bob{0%,100%{translate:0 0}50%{translate:0 -8px}}\n.hero-art .a{transform:translate(-36px,18px) rotate(-3deg)}\n.hero-art .b{transform:translate(40px,28px) rotate(2deg)}\n.loaded .hero-art .b{transition-delay:150ms}\n.loaded .hero-art .a{animation:bob 7s ease-in-out 1.2s infinite}\n.loaded .hero-art .b{animation:bob 7s ease-in-out 2.4s infinite}\n.hero-copy>*{opacity:0;transform:translateY(14px);transition:opacity 600ms var(--ease-out),transform 600ms var(--ease-out)}\n.loaded .hero-copy>*{opacity:1;transform:none}\n.loaded .hero-copy>:nth-child(2){transition-delay:70ms}.loaded .hero-copy>:nth-child(3){transition-delay:140ms}.loaded .hero-copy>:nth-child(4){transition-delay:210ms}.loaded .hero-copy>:nth-child(5){transition-delay:280ms}\n\n@media (prefers-reduced-motion:reduce){\n  html{scroll-behavior:auto}\n  *,*::before,*::after{animation:none!important;transition-duration:.01ms!important;transition-delay:0ms!important}\n  .rv,.hero-copy>*,.hero-art img,.node,.link-v,.fork,.join{opacity:1!important;transform:none!important}\n  .steps{--line:1!important}\n}\n.no-js .rv,.no-js .hero-copy>*,.no-js .hero-art img,.no-js .node,.no-js .link-v,.no-js .fork,.no-js .join{opacity:1;transform:none}\n.no-js .steps{--line:1}\n\n\/* Glycedil Duo additions *\/\n.chip.t{background:#3d66ad;color:#fff}.chip.g{background:#fff;color:#8e1f71}\n.cards.c3{grid-template-columns:repeat(3,1fr)}\n@media (max-width:900px){.cards.c3{grid-template-columns:1fr}}\n.card-h{display:flex;align-items:center;gap:14px;margin-bottom:10px}\n.card-h .ico{margin-bottom:0;flex:none}\n.card-h h3{margin-bottom:0}\n.lead{max-width:80ch;margin-bottom:28px;color:var(--ink)}\n.cards.c2{margin-bottom:20px}\n.cards.c2 .card.wide{grid-column:1\/-1}\n.card ul{list-style:none;padding:0;display:grid;gap:10px}\n.card li{position:relative;padding-left:20px;color:var(--ink-muted);font-size:16.5px}\n.card li::before{content:\"\";position:absolute;left:0;top:.65em;width:8px;height:8px;border-radius:50%;background:var(--teal-2)}\n.card.wide ul{grid-template-columns:repeat(3,1fr);gap:18px 28px}\n@media (max-width:900px){.card.wide ul{grid-template-columns:1fr}}\n.pcard{flex-wrap:wrap}\n.pcard .dose{font-size:clamp(34px,4.5vw,44px)}\n.pcard h3{font-size:16px}\n.pcard.a2{--c:#3d66ad}\n.cols{display:grid;grid-template-columns:1fr 1fr;gap:12px;max-width:360px;margin-inline:auto}\n.col{display:flex;flex-direction:column;align-items:stretch}\n.col .node{max-width:none;width:100%;font-size:13px;padding:9px 8px}\n.col .node small{font-size:11px}\n.col .link-v{height:26px;flex:none}\n.node.lime{background:#3d66ad;border-color:#3d66ad;color:#fff;border-radius:999px;padding:9px 8px}\n.node.blue{background:var(--action-teal);border-color:var(--action-teal);color:#fff;border-radius:999px;padding:9px 8px}\n.join{max-width:360px;height:16px;margin-inline:auto;position:relative;opacity:0;transition:opacity 400ms var(--ease-out);transition-delay:calc(var(--i)*220ms)}\n.flow.in .join{opacity:1}\n.join::before{content:\"\";position:absolute;left:25%;right:25%;bottom:0;height:16px;border:2px solid var(--action-teal);border-top:0}\n.join::after{content:\"\";position:absolute;left:50%;bottom:-14px;height:14px;width:2px;background:var(--action-teal)}\n.fork2{max-width:360px}\n.node.end small{color:#fff;opacity:.92}\n.dn{color:#9a2279;font-weight:600}\n.node.end .dn{color:#fff}\n.note-box.has-bg ul{list-style:none;padding:0;display:grid;gap:12px;max-width:80ch}\n.note-box.has-bg li{position:relative;padding-left:20px;font-size:17.5px;line-height:1.6;color:#fff}\n.note-box.has-bg li::before{content:\"\";position:absolute;left:0;top:.7em;width:8px;height:8px;border-radius:50%;background:#e3cdd9}\n.specs dd{overflow-wrap:break-word;word-break:normal;hyphens:none}.specs li:first-child{flex:1.6}\n[type=\"button\"]:hover{background-color:transparent;color:var(--teal-head)}\n[type=\"button\"]:focus{background-color:transparent;color:var(--teal-head)}\n<\/style>\n<script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"What is Glycedil Duo?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Glycedil Duo combines Sitagliptin and Metformin in an oral-release tablet, specifically designed for the management of type 2 diabetes in adults. This combination takes advantage of the complementary mechanisms of both drugs to improve glycemic control, with a low risk of hypoglycemia when used without insulin or sulfonylureas.\"}}, {\"@type\": \"Question\", \"name\": \"What is Glycedil Duo indicated for?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Glycedil Duo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, particularly in patients inadequately controlled on metformin alone or those already receiving sitagliptin and metformin in combination.\"}}, {\"@type\": \"Question\", \"name\": \"How does Glycedil Duo work?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, improving insulin secretion and reducing glucagon. Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they offer effective control of postprandial and basal glucose.\"}}, {\"@type\": \"Question\", \"name\": \"How is Glycedil Duo dosed and administered?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Dosage should be personalized based on the patient\u2019s current response to treatment. Typical starting dose: one tablet containing Sitagliptin 50 mg and Metformin 1000 mg twice daily, with meals to reduce gastrointestinal effects. Dose adjustments may include increases up to Sitagliptin 100 mg and Metformin 1000 mg twice daily according to need and tolerance.\"}}, {\"@type\": \"Question\", \"name\": \"What are the benefits of Glycedil Duo?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"The combination in a single tablet facilitates treatment adherence, reducing the daily medication burden. Improves glycemic control more effectively than monotherapy with either component. Associated with a low risk of hypoglycemia compared with other antidiabetic agents.\"}}, {\"@type\": \"Question\", \"name\": \"What are the clinical considerations for Glycedil Duo?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Start treatment only after evaluating renal function and verifying the adequacy of the patient\u2019s diet and exercise. Adjust the dose based on blood glucose control and the patient\u2019s tolerance. Monitor renal function regularly, especially in elderly patients or those at risk of renal impairment.\"}}, {\"@type\": \"Question\", \"name\": \"What are the safety and precautionary measures for Glycedil Duo?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Monitor renal function at least once a year, or more frequently in patients with risk factors for renal impairment. Use with caution in patients at risk of lactic acidosis, especially those with renal or hepatic insufficiency. Contraindicated in patients with severe renal insufficiency, active liver disease or metabolic acidosis, including diabetic ketoacidosis.\"}}, {\"@type\": \"Question\", \"name\": \"Which strengths and presentation are available?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Glycedil Duo is available as Sitagliptin 100 mg \/ Metformin 1000 mg and Sitagliptin 50 mg \/ Metformin 1000 mg, in a box of 30 tablets, following the British Pharmacopoeia standard.\"}}, {\"@type\": \"Question\", \"name\": \"How is Glycedil Duo manufactured?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Glycedil Duo is manufactured according to the strict specifications of the British Pharmacopoeia to ensure consistency and superior quality. Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.\"}}]}<\/script>\n<\/head>\n<body class=\"no-js\">\n<a class=\"skip\" href=\"#main\">Skip to content<\/a>\n<span id=\"top\"><\/span>\n\n\n<main id=\"main\">\n<section class=\"hero\" aria-labelledby=\"h1\" style=\"padding:0\">\n  <canvas id=\"fx\" aria-hidden=\"true\"><\/canvas>\n  <div class=\"cx-wrap\">\n    <div class=\"hero-copy\">\n      <span class=\"tag\">DPP-4 Inhibitor + Biguanide \u00b7 Type 2 Diabetes<\/span>\n      <h1 id=\"h1\">Glycedil Duo<sup>\u00ae<\/sup><\/h1>\n      <p class=\"generic\">Sitagliptin \/ Metformin<\/p>\n      <div class=\"strengths\" role=\"list\">\n        <span class=\"chip t\" role=\"listitem\">100 mg \/ 1000 mg<\/span>\n        <span class=\"chip g\" role=\"listitem\">50 mg \/ 1000 mg<\/span>\n      <\/div>\n      <div class=\"cta-row\">\n        <a class=\"btn btn-primary\" href=\"#mechanism\">Pharmacological Properties<\/a>\n      <\/div>\n    <\/div>\n    <div class=\"hero-art\">\n      <img fetchpriority=\"high\" decoding=\"async\" class=\"a\" src=\"https:\/\/crassulapharma.com\/wp-content\/uploads\/2026\/10\/box-glycedil-duo-100.png\" alt=\"Glycedil Duo sitagliptin \/ metformin 100 mg \/ 1000 mg box\" width=\"1396\" height=\"1048\" title=\"\">\n      <img decoding=\"async\" class=\"b\" src=\"https:\/\/crassulapharma.com\/wp-content\/uploads\/2026\/10\/box-glycedil-duo-50.png\" alt=\"Glycedil Duo sitagliptin \/ metformin 50 mg \/ 1000 mg box\" width=\"1396\" height=\"1057\" title=\"\">\n    <\/div>\n  <\/div>\n<\/section>\n\n<div class=\"specs\">\n  <div class=\"cx-wrap\">\n    <ul>\n      <li><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><rect x=\"2.5\" y=\"8\" width=\"19\" height=\"8\" rx=\"4\"\/><path d=\"M12 8v8\"\/><\/svg><\/span><dl><dt>Active ingredients<\/dt><dd>Sitagliptin + Metformin<\/dd><\/dl><\/li>\n      <li><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M12 12c-2-3-3.5-4-5.5-4a4 4 0 0 0 0 8c2 0 3.5-1 5.5-4Zm0 0c2 3 3.5 4 5.5 4a4 4 0 0 0 0-8c-2 0-3.5 1-5.5 4Z\"\/><\/svg><\/span><dl><dt>Strength<\/dt><dd>100 mg \/ 1000 mg \u00b7 50 mg \/ 1000 mg<\/dd><\/dl><\/li>\n      <li><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M21 8 12 3 3 8v8l9 5 9-5V8Z\"\/><path d=\"m3 8 9 5 9-5M12 13v8\"\/><\/svg><\/span><dl><dt>Presentation<\/dt><dd>Box of 30 tablets<\/dd><\/dl><\/li>\n      <li><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><rect x=\"5\" y=\"3\" width=\"14\" height=\"18\" rx=\"3\"\/><path d=\"M9 8h6M9 12h6M9 16h3\"\/><\/svg><\/span><dl><dt>Standard<\/dt><dd>British Pharmacopoeia<\/dd><\/dl><\/li>\n    <\/ul>\n  <\/div>\n<\/div>\n\n<section class=\"about\" aria-labelledby=\"what\">\n  <div class=\"cx-wrap split\">\n    <div class=\"prose rv\">\n    <h2 class=\"h2\" id=\"what\">What is Glycedil Duo?<\/h2>\n    <p><strong>Glycedil Duo<\/strong> combines Sitagliptin and Metformin in an oral-release tablet, specifically designed for the management of type 2 diabetes in adults. This combination takes advantage of the complementary mechanisms of both drugs to improve glycemic control, with a low risk of hypoglycemia when used without insulin or sulfonylureas.<\/p>\n    <\/div>\n    <div class=\"media-wrap rv\" style=\"--d:1\"><div class=\"media\"><img loading=\"lazy\" src=\"https:\/\/crassulapharma.com\/wp-content\/uploads\/2026\/10\/info-glycedil-duo.jpg\" alt=\"\" width=\"1600\" height=\"1200\" loading=\"lazy\" decoding=\"async\" title=\"\"><\/div><\/div>\n  <\/div>\n<\/section>\n\n<section class=\"indications\" id=\"indications\" aria-labelledby=\"ind\">\n  <div class=\"cx-wrap\">\n    <h2 class=\"h2 rv\" id=\"ind\">Indications<\/h2>\n    <p class=\"lead rv\">Glycedil Duo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, particularly in patients inadequately controlled on metformin alone or those already receiving sitagliptin and metformin in combination.<\/p>\n    <div class=\"cards c3\">\n      <article class=\"card rv\" style=\"--d:0\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M3 12h4l2.5-6 4 12 2.5-6h5\"\/><\/svg><\/span><h3>Inadequately Controlled Type 2 Diabetes<\/h3><\/div>\n        <p>For patients inadequately controlled on metformin alone.<\/p>\n      <\/article>\n      <article class=\"card rv\" style=\"--d:1\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M12 3s6 6.5 6 11a6 6 0 0 1-12 0c0-4.500 6-11 6-11Z\"\/><path d=\"M12 14v3\"\/><\/svg><\/span><h3>Blood Glucose Stabilization<\/h3><\/div>\n        <p>As part of a comprehensive regimen that includes diet and exercise.<\/p>\n      <\/article>\n      <article class=\"card rv\" style=\"--d:2\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M12 3 4 6v6c0 4.500 3.500 7.500 8 9 4.500-1.500 8-4.500 8-9V6l-8-3Z\"\/><path d=\"m8.500 12 2.500 2.500L15.500 10\"\/><\/svg><\/span><h3>Improved Glycemic Control<\/h3><\/div>\n        <p>Helps improve glycemic control in adults with type 2 diabetes.<\/p>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section class=\"presentations\" id=\"presentations\" aria-labelledby=\"pres\">\n  <div class=\"cx-wrap\">\n    <h2 class=\"h2 rv\" id=\"pres\">Presentations<\/h2>\n    <div class=\"pres\">\n      <article class=\"pcard rv\" style=\"--c:#3d66ad;--d:0\">\n        <div class=\"dose\">100\/1000<small>mg<\/small><\/div>\n        <div><h3>Sitagliptin 100 mg \/ Metformin 1000 mg<\/h3><p>Box of 30 tablets \u00b7 British Pharmacopoeia<\/p><\/div>\n      <\/article>\n      <article class=\"pcard a2 rv\" style=\"--d:1\">\n        <div class=\"dose\">50\/1000<small>mg<\/small><\/div>\n        <div><h3>Sitagliptin 50 mg \/ Metformin 1000 mg<\/h3><p>Box of 30 tablets \u00b7 British Pharmacopoeia<\/p><\/div>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"mechanism\" aria-labelledby=\"moa\">\n  <div class=\"cx-wrap\">\n    <h2 class=\"h2 rv\" id=\"moa\">Pharmacological Properties<\/h2>\n    <div class=\"mech-grid\">\n      <ol class=\"steps\" id=\"steps\">\n        <li class=\"rv\"><span class=\"num\">1<\/span><h3>Sitagliptin<\/h3><p>Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, improving insulin secretion and reducing glucagon.<\/p><\/li>\n        <li class=\"rv\"><span class=\"num\">2<\/span><h3>Metformin<\/h3><p>Metformin improves insulin sensitivity and reduces hepatic glucose production.<\/p><\/li>\n        <li class=\"rv\"><span class=\"num\">3<\/span><h3>Combined Action<\/h3><p>Together, they offer effective control of postprandial and basal glucose.<\/p><\/li>\n      <\/ol>\n\n      <div class=\"flow\" id=\"flow\" role=\"group\" aria-label=\"How Glycedil Duo works\">\n        <p class=\"flow-title\">How Glycedil Duo works<\/p>\n        <span class=\"node primary\" style=\"--i:0\">Glycedil Duo\u00ae<\/span>\n        <div class=\"fork\" style=\"--i:1;max-width:360px\"><i><\/i><i><\/i><\/div>\n        <div class=\"cols\">\n          <div class=\"col\">\n            <span class=\"node blue\" style=\"--i:2\">Sitagliptin<\/span>\n            <div class=\"link-v\" style=\"--i:3\"><\/div>\n            <span class=\"node\" style=\"--i:4\">DPP-4 inhibition<\/span>\n            <div class=\"link-v\" style=\"--i:5\"><\/div>\n            <span class=\"node\" style=\"--i:6\"><span class=\"dn\">\u2191<\/span> Incretin hormones<\/span>\n            <div class=\"link-v\" style=\"--i:7\"><\/div>\n            <span class=\"node\" style=\"--i:8\"><span class=\"dn\">\u2191<\/span> Insulin \u00b7 <span class=\"dn\">\u2193<\/span> Glucagon<\/span>\n            <div class=\"link-v nohead\" style=\"--i:9\"><\/div>\n          <\/div>\n          <div class=\"col\">\n            <span class=\"node lime\" style=\"--i:2\">Metformin<\/span>\n            <div class=\"link-v\" style=\"--i:3\"><\/div>\n            <span class=\"node\" style=\"--i:4\"><span class=\"dn\">\u2191<\/span> Insulin sensitivity<\/span>\n            <div class=\"link-v\" style=\"--i:5\"><\/div>\n            <span class=\"node\" style=\"--i:6\"><span class=\"dn\">\u2193<\/span> Hepatic glucose production<\/span>\n            <div class=\"link-v nohead\" style=\"--i:7;flex:1;height:auto;min-height:26px\"><\/div>\n          <\/div>\n        <\/div>\n        <div class=\"join\" style=\"--i:10\"><\/div>\n        <div style=\"height:14px\"><\/div>\n        <span class=\"node end\" style=\"--i:11\">Postprandial &amp; basal glucose control<\/span>\n      <\/div>\n    <\/div>\n\n    <div class=\"cards c2\" style=\"margin-top:56px\">\n      <article class=\"card rv\" style=\"--d:0\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><circle cx=\"12\" cy=\"12\" r=\"9\"\/><path d=\"M12 7v5l3 2\"\/><\/svg><\/span><h3>Dosage and Administration<\/h3><\/div>\n        <ul><li>Dosage should be personalized based on the patient\u2019s current response to treatment.<\/li><li>Typical starting dose: one tablet containing Sitagliptin 50 mg and Metformin 1000 mg twice daily, with meals to reduce gastrointestinal effects.<\/li><li>Dose adjustments may include increases up to Sitagliptin 100 mg and Metformin 1000 mg twice daily according to need and tolerance.<\/li><\/ul>\n      <\/article>\n      <article class=\"card rv\" style=\"--d:1\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><rect x=\"2.5\" y=\"8\" width=\"19\" height=\"8\" rx=\"4\"\/><path d=\"M12 8v8\"\/><\/svg><\/span><h3>Benefits of Glycedil Duo<\/h3><\/div>\n        <ul><li>The combination in a single tablet facilitates treatment adherence, reducing the daily medication burden.<\/li><li>Improves glycemic control more effectively than monotherapy with either component.<\/li><li>Associated with a low risk of hypoglycemia compared with other antidiabetic agents.<\/li><\/ul>\n      <\/article>\n      <article class=\"card wide rv\" style=\"--d:2\">\n        <div class=\"card-h\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M9 3h6M10 3v6l-5 9a2 2 0 0 0 1.800 3h10.400a2 2 0 0 0 1.800-3l-5-9V3\"\/><path d=\"M7.500 15h9\"\/><\/svg><\/span><h3>Clinical Considerations<\/h3><\/div>\n        <ul><li>Start treatment only after evaluating renal function and verifying the adequacy of the patient\u2019s diet and exercise.<\/li><li>Adjust the dose based on blood glucose control and the patient\u2019s tolerance.<\/li><li>Monitor renal function regularly, especially in elderly patients or those at risk of renal impairment.<\/li><\/ul>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section class=\"note\" aria-labelledby=\"imp\">\n  <div class=\"cx-wrap\">\n    <div class=\"note-box has-bg rv\" style=\"--ov:63,11,50\">\n      <div class=\"bg\" aria-hidden=\"true\"><img loading=\"lazy\" src=\"https:\/\/crassulapharma.com\/wp-content\/uploads\/2026\/10\/info-glycedil-duo.jpg\" alt=\"\" width=\"1600\" height=\"1200\" loading=\"lazy\" decoding=\"async\" title=\"\"><\/div>\n      <h3 id=\"imp\"><span class=\"ico\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M12 3 2.500 20h19L12 3Z\"\/><path d=\"M12 10v4.500M12 17.200v.1\"\/><\/svg><\/span>Safety and Precautionary Measures<\/h3>\n      <ul>\n        <li>Monitor renal function at least once a year, or more frequently in patients with risk factors for renal impairment.<\/li>\n        <li>Use with caution in patients at risk of lactic acidosis, especially those with renal or hepatic insufficiency.<\/li>\n        <li>Contraindicated in patients with severe renal insufficiency, active liver disease or metabolic acidosis, including diabetic ketoacidosis.<\/li>\n      <\/ul>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section class=\"faq\" id=\"faq\" aria-labelledby=\"faq-h\">\n  <div class=\"cx-wrap\">\n    <h2 class=\"h2 rv\" id=\"faq-h\">Frequently Asked Questions<\/h2>\n    <div class=\"faq-list\">\n      <div class=\"faq-item rv\" style=\"--d:0\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q1\" aria-expanded=\"false\" aria-controls=\"faq-a1\"><span>What is Glycedil Duo?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a1\" role=\"region\" aria-labelledby=\"faq-q1\"><div><p><strong>Glycedil Duo<\/strong> combines Sitagliptin and Metformin in an oral-release tablet, specifically designed for the management of type 2 diabetes in adults. This combination takes advantage of the complementary mechanisms of both drugs to improve glycemic control, with a low risk of hypoglycemia when used without insulin or sulfonylureas.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:1\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q2\" aria-expanded=\"false\" aria-controls=\"faq-a2\"><span>What is Glycedil Duo indicated for?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a2\" role=\"region\" aria-labelledby=\"faq-q2\"><div><p>Glycedil Duo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, particularly in patients inadequately controlled on metformin alone or those already receiving sitagliptin and metformin in combination.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:2\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q3\" aria-expanded=\"false\" aria-controls=\"faq-a3\"><span>How does Glycedil Duo work?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a3\" role=\"region\" aria-labelledby=\"faq-q3\"><div><p>Sitagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, improving insulin secretion and reducing glucagon. Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they offer effective control of postprandial and basal glucose.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:3\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q4\" aria-expanded=\"false\" aria-controls=\"faq-a4\"><span>How is Glycedil Duo dosed and administered?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a4\" role=\"region\" aria-labelledby=\"faq-q4\"><div><p>Dosage should be personalized based on the patient\u2019s current response to treatment. Typical starting dose: one tablet containing Sitagliptin 50 mg and Metformin 1000 mg twice daily, with meals to reduce gastrointestinal effects. Dose adjustments may include increases up to Sitagliptin 100 mg and Metformin 1000 mg twice daily according to need and tolerance.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:4\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q5\" aria-expanded=\"false\" aria-controls=\"faq-a5\"><span>What are the benefits of Glycedil Duo?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a5\" role=\"region\" aria-labelledby=\"faq-q5\"><div><p>The combination in a single tablet facilitates treatment adherence, reducing the daily medication burden. Improves glycemic control more effectively than monotherapy with either component. Associated with a low risk of hypoglycemia compared with other antidiabetic agents.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:4\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q6\" aria-expanded=\"false\" aria-controls=\"faq-a6\"><span>What are the clinical considerations for Glycedil Duo?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a6\" role=\"region\" aria-labelledby=\"faq-q6\"><div><p>Start treatment only after evaluating renal function and verifying the adequacy of the patient\u2019s diet and exercise. Adjust the dose based on blood glucose control and the patient\u2019s tolerance. Monitor renal function regularly, especially in elderly patients or those at risk of renal impairment.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:4\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q7\" aria-expanded=\"false\" aria-controls=\"faq-a7\"><span>What are the safety and precautionary measures for Glycedil Duo?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a7\" role=\"region\" aria-labelledby=\"faq-q7\"><div><p>Monitor renal function at least once a year, or more frequently in patients with risk factors for renal impairment. Use with caution in patients at risk of lactic acidosis, especially those with renal or hepatic insufficiency. Contraindicated in patients with severe renal insufficiency, active liver disease or metabolic acidosis, including diabetic ketoacidosis.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:4\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q8\" aria-expanded=\"false\" aria-controls=\"faq-a8\"><span>Which strengths and presentation are available?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a8\" role=\"region\" aria-labelledby=\"faq-q8\"><div><p>Glycedil Duo is available as Sitagliptin 100 mg \/ Metformin 1000 mg and Sitagliptin 50 mg \/ Metformin 1000 mg, in a box of 30 tablets, following the British Pharmacopoeia standard.<\/p><\/div><\/div>\n      <\/div>\n      <div class=\"faq-item rv\" style=\"--d:4\">\n        <h3><button class=\"faq-q\" type=\"button\" id=\"faq-q9\" aria-expanded=\"false\" aria-controls=\"faq-a9\"><span>How is Glycedil Duo manufactured?<\/span><span class=\"faq-ico\" aria-hidden=\"true\"><svg viewBox=\"0 0 16 16\"><path d=\"M8 2v12M2 8h12\"\/><\/svg><\/span><\/button><\/h3>\n        <div class=\"faq-a\" id=\"faq-a9\" role=\"region\" aria-labelledby=\"faq-q9\"><div><p>Glycedil Duo is manufactured according to the strict specifications of the British Pharmacopoeia to ensure consistency and superior quality. Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.<\/p><\/div><\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section class=\"quality\" id=\"quality\" aria-labelledby=\"qs\">\n  <div class=\"cx-wrap\">\n    <div class=\"qbox rv\">\n      <h2 id=\"qs\">Quality &amp; Standards<\/h2>\n      <div class=\"qgrid\">\n        <img decoding=\"async\" class=\"gmp\" src=\"https:\/\/crassulapharma.com\/wp-content\/uploads\/2026\/10\/logo-gmp.png\" alt=\"GMP Certified Quality\" width=\"112\" height=\"112\" title=\"\">\n        <div class=\"check\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><circle cx=\"12\" cy=\"12\" r=\"9.5\"\/><path d=\"m8 12.5 2.7 2.7L16 9.5\"\/><\/svg><p>Manufactured according to the strict specifications of the British Pharmacopoeia to ensure consistency and superior quality.<\/p><\/div>\n        <div class=\"check\"><svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><circle cx=\"12\" cy=\"12\" r=\"9.5\"\/><path d=\"m8 12.5 2.7 2.7L16 9.5\"\/><\/svg><p>Crassula Pharma certifies that all our products are manufactured in accordance with GMP parameters.<\/p><\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n<\/main>\n\n\n<script>\n(function(){\n  var d=document.documentElement,b=document.body;\n  b.classList.remove('no-js');\n  requestAnimationFrame(function(){requestAnimationFrame(function(){b.classList.add('loaded')})});\n\n  var io=new IntersectionObserver(function(es){es.forEach(function(e){\n    if(e.isIntersecting){e.target.classList.add('in');io.unobserve(e.target)}})},{threshold:.15,rootMargin:'0px 0px -6% 0px'});\n  document.querySelectorAll('.rv').forEach(function(el){io.observe(el)});\n\n\n  (function(){\n    var c=document.getElementById('fx');if(!c||!c.getContext)return;\n    var ctx=c.getContext('2d'),hero=c.parentElement,W=0,H=0,dpr=1,P=[],run=false,raf=0,mx=-999,my=-999;\n    var reduce=matchMedia('(prefers-reduced-motion: reduce)').matches;\n    function size(){var r=hero.getBoundingClientRect();dpr=Math.min(devicePixelRatio||1,2);W=r.width;H=r.height;c.width=W*dpr;c.height=H*dpr;ctx.setTransform(dpr,0,0,dpr,0,0);\n      var n=Math.round(Math.min(90,Math.max(28,W*H\/16000)));P=[];\n      for(var i=0;i<n;i++)P.push({x:Math.random()*W,y:Math.random()*H,vx:(Math.random()-.5)*.28,vy:(Math.random()-.5)*.28,r:Math.random()*1.4+.8});}\n    function draw(){\n      ctx.clearRect(0,0,W,H);var L=Math.min(150,W\/7);\n      for(var i=0;i<P.length;i++){var a=P[i];\n        if(!reduce){a.x+=a.vx;a.y+=a.vy;if(a.x<0||a.x>W)a.vx*=-1;if(a.y<0||a.y>H)a.vy*=-1;\n          var dx=a.x-mx,dy=a.y-my,d=dx*dx+dy*dy;if(d<14400){var f=(1-Math.sqrt(d)\/120)*.6;a.x+=dx*f*.02;a.y+=dy*f*.02}}\n        for(var j=i+1;j<P.length;j++){var b=P[j],ex=a.x-b.x,ey=a.y-b.y,e=ex*ex+ey*ey;\n          if(e<L*L){ctx.strokeStyle='rgba(224,196,236,'+(.22*(1-Math.sqrt(e)\/L))+')';ctx.lineWidth=1;ctx.beginPath();ctx.moveTo(a.x,a.y);ctx.lineTo(b.x,b.y);ctx.stroke()}}\n        ctx.fillStyle='rgba(240,222,247,.75)';ctx.beginPath();ctx.arc(a.x,a.y,a.r,0,6.2832);ctx.fill();}\n      if(run&&!reduce)raf=requestAnimationFrame(draw);}\n    function start(){if(!run){run=true;raf=requestAnimationFrame(draw)}}\n    function stop(){run=false;cancelAnimationFrame(raf)}\n    size();draw();\n    var rt;addEventListener('resize',function(){clearTimeout(rt);rt=setTimeout(function(){size();draw()},150)});\n    hero.addEventListener('pointermove',function(e){var r=hero.getBoundingClientRect();mx=e.clientX-r.left;my=e.clientY-r.top},{passive:true});\n    hero.addEventListener('pointerleave',function(){mx=my=-999});\n    new IntersectionObserver(function(es){es[0].isIntersecting?start():stop()}).observe(hero);\n  })();\n\n  document.querySelectorAll('.faq-q').forEach(function(b){\n    b.addEventListener('click',function(){\n      var it=b.closest('.faq-item'),open=it.classList.toggle('open');\n      b.setAttribute('aria-expanded',open?'true':'false');\n    });\n  });\n  var flow=document.getElementById('flow');\n  var fio=new IntersectionObserver(function(es){es.forEach(function(e){if(e.isIntersecting){flow.classList.add('in');fio.disconnect()}})},{threshold:.25});\n  fio.observe(flow);\n\n  var steps=document.getElementById('steps');\n  function line(){var r=steps.getBoundingClientRect(),h=innerHeight;\n    var p=Math.min(1,Math.max(0,(h*.75-r.top)\/r.height));steps.style.setProperty('--line',p)}\n  addEventListener('scroll',line,{passive:true});line();\n\n})();\n<\/script>\n<\/body>\n<\/html>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Glycedil Duo\u00ae (Sitagliptin \/ Metformin) \u2013 Crassula Skip to content DPP-4 Inhibitor + Biguanide \u00b7 Type 2 Diabetes Glycedil Duo\u00ae Sitagliptin \/ Metformin 100 mg \/ 1000 mg 50 mg \/ 1000 mg Pharmacological Properties Active ingredients Sitagliptin + Metformin Strength 100 mg \/ 1000 mg \u00b7 50 mg \/ 1000 mg Presentation Box of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-11932","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/pages\/11932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/comments?post=11932"}],"version-history":[{"count":10,"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/pages\/11932\/revisions"}],"predecessor-version":[{"id":12124,"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/pages\/11932\/revisions\/12124"}],"wp:attachment":[{"href":"https:\/\/crassulapharma.com\/es\/wp-json\/wp\/v2\/media?parent=11932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}